Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Slides:

Advertisements

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Advertisements

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP CHEST

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Advances in Molecular Biology of Lung Disease

by Rogelio Zamilpa, and Merry L. Lindsey

Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT Jacob M. Kaufman,

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era Joon H. Uhm, MD, Alyx B. Porter,

cMET Exon 14 Skipping: From the Structure to the Clinic

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Ground glass opacities: Imaging, pathology, and gene mutations

Kinase inhibitors: Vice becomes virtue

Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway Gozde Akgumus, Fengqi.

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD

GLP-1–Based Therapies: The Dilemma of Uncertainty

In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies Michael J. Bertoldo, Kirsty A. Walters, William.

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and survival. Schematic view of Trk receptors.

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy Flavia.

Identification of TOR Signaling Complexes

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung.

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case? Monica Giovannini, MD, Carmen.

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Nat. Rev. Urol. doi: /nrurol

BRAF Alterations as Therapeutic Targets in Non–Small-Cell Lung Cancer

Vascular Endothelial Growth Factor (VEGF) Pathway

FGFR Signaling as a Target for Lung Cancer Therapy

Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405.

Olga C. J. Schuurbiers, MD, Johannes H. A. M

Autophagy in kidney disease and aging: lessons from rodent models

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

An Emerging Role of mTOR in Lipid Biosynthesis

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing Marieke Hylebos, MSc, Guy Van Camp, PhD, Jan P van.

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET- Mutated Tumor Marc-Antoine Benderra, MD, Sandrine Aspeslagh, PhD, Sophie.

Clinicopathologic Features of Advanced Squamous NSCLC

Volume 73, Issue 1, Pages 5-7 (January 2008)

Volume 139, Issue 2, Pages e3 (August 2010)

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench Kenichi Suda, MD, PhD, Paul A. Bunn,

Inderpal S. Sarkaria, MD, Maureen F

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

AKT/PKB Signaling: Navigating Downstream

Erratum Journal of Thoracic Oncology

SRC and STAT Pathways Journal of Thoracic Oncology

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Jinhua Tang, Na Liu, Shougang Zhuang Kidney International

Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn Kidney International

Regina M. Vidaver, PhD, Beth S. Schachter, PhD

Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing Richard A.F. Clark,

Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma Filippo Lococo, MD,

Update on the Medical Treatment of Metastatic Renal Cell Carcinoma

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 6, Pages 947-953 (June 2012) DOI: 10.1097/JTO.0b013e31825581bd Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 mTOR-signaling network. Activated growth factor receptors trigger activation of the PI3K/Akt pathways and the Ras/MEK/Erk pathway. Activated Akt leads to increased mTOR activity through signaling by means of the TSC1/2 complex. mTOR then phosphorylates S6K1 and 4E-BP1, resulting in increased gene transcription, cell growth, and cell proliferation. PI3-K, phosphatidylinositol 3-kinase; AMPK, adenosine mono-phosphate-activated protein kinase; LKB1, liver kinase B1; PTEN, phosphatase and tensin homologue; STRAD, Ste20-like adaptor protein; TSC, tuberous sclerosis complex; EGFR, epidermal growth factor receptor; mTOR, mammalian target of rapamycin; m, signaling proteins frequently mutated in lung cancer; bm, potential as biomarker; Ras, ras2 Kirsten rat sarcoma viral oncogene homolog; MEK, MAPK/ERK kinase; Erk, extracellular signal-regulated kinase. Journal of Thoracic Oncology 2012 7, 947-953DOI: (10.1097/JTO.0b013e31825581bd) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions